Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation.

Jana K StrieflerJens M StielerChristopher C M NeumannDominik GeiselPirus GhadjarMarianne SinnThomas MalinkaJohann PratschkeSebastian StinzingHelmut OettleHanno RiessUwe Pelzer

Published in: Journal of clinical medicine (2022)

The combination of lapatinib 1250 mg OD with platinum-containing chemotherapy is safe and feasible in patients with refractory pancreatic cancer and warrants further investigation.

Keyphrases

locally advanced
small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
cancer therapy
drug delivery